Related Experiment Video
Updated: Sep 22, 2025

06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
5.8K
IL6 Blockade Reduces Immunotherapy-Induced Immune-Related Adverse Events
Cancer Discovery
|May 20, 2022
IL6 can mediate the immune-related adverse events (irAE) observed with immune checkpoint blockade (ICB).
IL6 can mediate the immune-related adverse events (irAE) observed with immune checkpoint blockade (ICB).
More Related Videos
Related Concept Videos
Tumor Immunotherapy
681
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
681
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
281
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
281
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
243
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
243

